Catalog No.
DHH31001
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG2-lambda
Clonality
Monoclonal
Target
CGRP type 1 receptor, CGRPR, Calcitonin receptor-like receptor, CALCRL, Calcitonin gene-related peptide type 1 receptor
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q16602
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
AMG 334, erenumab-aooe, CAS: 1582205-90-0
Clone ID
Erenumab
A Controlled Trial of Erenumab for Episodic Migraine, PMID: 29171821
Erenumab in the treatment of migraine, PMID: 30235976
Erenumab-aooe, PMID: 30559520
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine, PMID: 29471679
The role of erenumab in the treatment of migraine, PMID: 32523630
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial, PMID: 28460892
Erenumab for episodic migraine prophylaxis, PMID: 30614741
Vascular safety of erenumab for migraine prevention, PMID: 31852816
Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study, PMID: 30996060
Erenumab for migraine, PMID: 30670893
Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention, PMID: 30813769
Erenumab safety and efficacy in migraine: A systematic review and meta-analysis of randomized clinical trials, PMID: 31876735
Erenumab: First Global Approval, PMID: 29968151
Early onset of efficacy with erenumab in patients with episodic and chronic migraine, PMID: 30276500
Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine, PMID: 32920850
Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial, PMID: 30996056
Efficacy and safety of erenumab in women with a history of menstrual migraine, PMID: 32746775
Erenumab, PMID: 31643409
Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine, PMID: 31085251
One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study, PMID: 32636324
Central effects of erenumab in migraine patients: An event-related functional imaging study, PMID: 32917805
Real-world effectiveness and tolerability of erenumab: A retrospective cohort study, PMID: 32791922
Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study, PMID: 30360965
Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination, PMID: 31159727
A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults, PMID: 31612482
Erenumab, PMID: 30000991
Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience, PMID: 32517693
Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety, PMID: 30793254
In brief: Erenumab (Aimovig) hypersensitivity, PMID: 31022159
A prospective real-world analysis of erenumab in refractory chronic migraine, PMID: 32487102
Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study, PMID: 32216456
Erenumab in Chronic Migraine: An Australian Experience, PMID: 32990364
Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study, PMID: 32493206
Migraine overview and summary of current and emerging treatment options, PMID: 30681821
Erenumab Side Effects, PMID: 31297805
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial, PMID: 33400330
Erenumab-Induced Severe Nausea Leading to Smoking Cessation: A Retrospective Case Series, PMID: 33202039
Erenumab does not alter cerebral hemodynamics and endothelial function in migraine without aura, PMID: 32867533
Hypertension: A new safety risk for patients treated with erenumab, PMID: 33423274
Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study, PMID: 29984601
Erenumab During Breastfeeding, PMID: 31381367
Erenumab is effective in reducing migraine frequency and improving physical functioning, PMID: 30108057
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine, PMID: 31146544
Predicting erenumab adverse events with single-cell genomics, PMID: 32653068
Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database, PMID: 33435709
Pharmacoeconomic Review Report: Erenumab (Aimovig): (Novartis Pharmaceuticals Canada Inc.) [Internet], PMID: 33476110
Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real-World Case Series, PMID: 32359106
Erenumab-aooe, Benralizumab, and Tezacaftor/ivacaftor, PMID: 30190109
Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study, PMID: 32547474
Clinical Review Report: Erenumab (Aimovig): (Novartis Pharmaceuticals Canada Inc.) [Internet], PMID: 33471453
For research use only. Not for human or drug use.
